Tehran – Head of Iran’s Atomic Energy Agency (AEOI) says heavy water derivatives and plasma medicine are opening new frontiers in drug development and treatment, and telling the key steps in the application of nuclear technology to public health.
Aeoi chief Mohammad Eslami said Tuesday that the field of heavy water derivatives has become a transformative field for medicines and is now a major part of the organization’s activities.
He announced that a new cooperative agreement has been signed to advance research and national projects in plasma medicine and will be described as a “collective will document” to enhance healthcare through advanced technology.
Eslami added that under the Ministry of Health Memorandum, clinical trials previously concentrated at Tehran University will be expanded to selected universities across the country.
“This will accelerate the spread of plasma-based technologies to various states,” he said.
The remarks came during a ceremony marking National Doctor’s Day. There, Eslami also emphasizes the success of AEOI in producing more than 70 types of radiopharmaceuticals, and is now supplied to more than 220 nuclear medicine centres in Iran and exported overseas. He said that while these products are used in diagnostics, palliative care and treatment, a further 20 radiopharmaceuticals are currently undergoing research and clinical trials.
Currently, Iran produces more than 70 types of radiopharmaceuticals and supplies over 220 nuclear medicine centres nationwide. According to Eslami, these products cover three categories: diagnosis, treatment and palliation.
In the field of diagnostics, advances are pushing forward the “frontier of knowledge” and improving accuracy so that doctors can better examine the patient’s body. On the treatment side, he added, the focus is on alleviating the suffering of patients while providing more effective treatment.
Eslami reveals that around 20 additional radiopharmaceuticals are currently in the research and clinical trial stages, reflecting Iran’s growth ability to integrate nuclear science into medicine.